Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome is characterized by skin rash, joint involvement, chronic meningitis with granulocytes and, in some cases, sensorineural hearing loss and ocular signs.
Features include always present findings: Skin rash and Hepatosplenomegaly; and very common findings: Hearing loss (hearing impairment), Uveitis, Joint inflammation (arthritis), and Meningitis and others. 54 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Seizure, Meningitis, Intellectual disability |
Bones and joints | 6 | Joint inflammation (arthritis), Abnormal joint morphology, Joint dislocation |
Blood and immune system | 4 | Low red blood cell count (anemia), Elevated white blood cell count (increased total leukocyte count), Enlarged spleen (splenomegaly) |
Eyes | 4 | Uveitis, Visual impairment, Blindness |
Skin | 4 | Lymphedema, Skin rash, Urticaria |
Digestive system | 4 | Hepatosplenomegaly, Enlarged spleen (splenomegaly), Nausea and vomiting |
Ears | 3 | Hearing loss (hearing impairment), Progressive sensorineural hearing impairment, Inner ear hearing loss (sensorineural hearing impairment) |
Metabolism | 2 | Recurrent fever, Fever |
Lab test results | 1 | Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration) |
Growth and development | 1 | Growth delay |
Head and neck | 1 | Macrocephaly |
Muscles | 1 | Myalgia |
Age of onset: at birth.
NLRP3 encodes NLR family pyrin domain containing 3 (1,036 aa). Sensor component of the NLRP3 inflammasome, which mediates inflammasome activation in response to defects in membrane integrity, leading to secretion of inflammatory cytokines IL1B and IL18 and pyroptosis. Highest expression in Whole Blood (23.3 TPM) and Lung (6.7 TPM).
CINCA syndrome is associated with mutations in the NLRP3 gene on chromosome 1.
The NLRP3 protein participates in CLEC7A/inflammasome pathway pathway.
NLRP3 is classified as a druggable target (Druggable Genome category) with score 5.8.
Genetic testing for NLRP3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for CINCA syndrome has been reported in the published literature.
1 FDA-approved treatment is available for CINCA syndrome, including ANAKINRA (KINERET, approved 2001).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
KINERET | ANAKINRA | — | 2001 | Available |
Gene therapy approaches for CINCA syndrome have been reported in the published literature.
1 trial found
Phenotype severity distribution: 2 always present features, 23 very common features, 19 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions, medical devices, gene therapy, and biologic therapy. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
89 publications have been identified in PubMed for CINCA syndrome. Research spans Basic Science / Preclinical (37%), Case Report / Case Series (22%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 33 | 37% |
Patient case studies | 20 | 22% |
Research summaries | 14 | 16% |
Clinical study results | 10 | 11% |
Testing and diagnosis research | 6 | 7% |
Disease patterns and progression | 5 | 6% |
New treatment approaches | 1 | 1% |
Balan K (2026). [PMID: 42264383](https://pubmed.ncbi.nlm.nih.gov/42264383/). *J Am Acad Dermatol*. [Review / Meta-Analysis]
Bouramtane A (2026). [PMID: 41261519](https://pubmed.ncbi.nlm.nih.gov/41261519/). *International journal of immunogenetics*. [Basic Science / Preclinical]
Aslani N (2026). [PMID: 42163195](https://pubmed.ncbi.nlm.nih.gov/42163195/). *BMC Pediatr*. [Case Report / Case Series]
Nicholas T (2026). [PMID: 41451028](https://pubmed.ncbi.nlm.nih.gov/41451028/). *JAAD case reports*. [Diagnostic / Biomarker]
Kawata Y (2026). [PMID: 41075074](https://pubmed.ncbi.nlm.nih.gov/41075074/). *Clinical journal of gastroenterology*. [Basic Science / Preclinical]
Gao FH (2026). [PMID: 41582757](https://pubmed.ncbi.nlm.nih.gov/41582757/). *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. [Case Report / Case Series]
Koga T (2026). [PMID: 41620931](https://pubmed.ncbi.nlm.nih.gov/41620931/). *Expert review of clinical immunology*. [Review / Meta-Analysis]
Levin JA (2026). [PMID: 41961992](https://pubmed.ncbi.nlm.nih.gov/41961992/). *A A Pract*. [Case Report / Case Series]
Toledano-Pinedo M (2026). [PMID: 41750257](https://pubmed.ncbi.nlm.nih.gov/41750257/). *Biomolecules*. [Basic Science / Preclinical]
Bourguiba R (2026). [PMID: 41933651](https://pubmed.ncbi.nlm.nih.gov/41933651/). *Clin Res Hepatol Gastroenterol*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about CINCA syndrome
AI-curated news mentioning CINCA syndrome
Updated Feb 6, 2026
A rare case report highlights the association of HPV-16 with hematocervix and hematometra, leading to cervical intraepithelial neoplasia (CIN). This study contributes to the understanding of HPV's role in rare gynecological conditions.